Genotyping Market Expected to Grow US$ 79,407.14 Million in 2028

The Strategic Insights and Development plans are also discussed and manufacturing processes and cost structures analyzed. Genotyping Market import/export consumption, supply and demand figures and cost price and production value gross margins are also provided.

The global genotyping market is expected to grow from US$ 25,191.28 million in 2022 to US$ 79,407.14 million by 2028; it is expected to grow with a CAGR of 20.1% from 2022 to 2028. The use of genotyping in drug development for genetic & rare diseases and rising R&D investments in pharmaceutical & biotechnology boost the global genotyping market growth.

Download PDF Sample Copy at:
https://www.theinsightpartners.com/sample/TIPHE100001166/?utm_source=OpenPR&utm_medium=10376

Top Companies are:

F. Hoffmann-La Roche Ltd.
Integrated DNA Technologies, Inc.
QIAGEN
MERCK KGaA
Eurofins Genomics
Thermo Fisher Scientific Inc
BioTek Instruments, Inc.
Xcelris Genomics
TrimGen Corporation
Illumina, Inc.

Report Segments:

Based on product and service, the genotyping market is segmented into instruments, reagents & kits, bioinformatics, and genotyping services. In 2022, the reagents and kits segment is estimated to hold the largest share of the market. The same segment is expected to register the highest CAGR from 2022 to 2028.

Based on technology, the genotyping market is segmented into microarrays, capillary electrophoresis, sequencing, matrix-assisted laser desorption/ionization-time of flight (Maldi-ToF), and mass spectrometry, polymerase chain reaction (PCR), and others. In 2022, the polymerase chain reaction (PCR) segment is estimated to hold the largest share of the market. The same segment is expected to register the highest CAGR from 2022 to 2028.

Have a Call with Analyst:
https://www.theinsightpartners.com/speak-to-analyst/TIPHE100001166/?utm_source=OpenPR&utm_medium=10376

Based on application, the genotyping market is segmented into pharmacogenomics, diagnostics & personalized medicine, animal genetics, agricultural biotechnology, and others. In 2022, the diagnostics & personalized medicine segment is expected to account for the largest share of the market. Moreover, the pharmacogenomics segment is expected to register the highest CAGR from 2022 to 2028.

Based on end user, the genotyping market is segmented into pharmaceutical and biopharmaceutical companies, diagnostic and research laboratories, academic institutes, and others. In 2022, the diagnostic and research laboratories segment is expected to account for the largest share of the market. Moreover, the pharmaceutical and biopharmaceutical companies segment is expected to register the highest CAGR from 2022 to 2028

Buy Report at:
https://www.theinsightpartners.com/buy/TIPHE100001166/?utm_source=OpenPR&utm_medium=10376

Contact us:

If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-987

About The Insight Partners:

The Insight Partners is a one top industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Manufacturing and Construction, Technology, Chemicals and Materials.
We offer our clients multiple ways to customize research as per their specific needs and budget.

This release was published on openPR.